February 22, 2021

Myovant Sciences to Present at Upcoming Investor Conferences

February 17, 2021

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

February 17, 2021

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

February 16, 2021

HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma

February 11, 2021

Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020

January 29, 2021

Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021

January 26, 2021

Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis

January 20, 2021

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

January 5, 2021

CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer